Biotechnology Company Regeneron to Buy 23andMe for $256 million
A look at why the publicly traded pharmaceutical giant is snapping the genetic-testing company out of bankruptcy.
A look at why the publicly traded pharmaceutical giant is snapping the genetic-testing company out of bankruptcy.
